KEGG   DISEASE: 卵巣癌
エントリ  
H00027                                                             

名称    
卵巣癌
概要    
Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.
カテゴリ  
がん
階層分類  
ヒト疾患 [BR:jp08402]
 がん
  乳房および女性生殖器のがん
   H00027  卵巣癌
ICD-11 による疾患分類 [BR:jp08403]
 02 Neoplasms
  Malignant neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C73  Malignant neoplasms of ovary
      H00027  卵巣癌
関連パスウェイ
hsa05200  Pathways in cancer
hsa05206  MicroRNAs in cancer
病因遺伝子 
BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
MSH2 (germline mutation) [HSA:4436] [KO:K08735]
MLH1 (germline mutation) [HSA:4292] [KO:K08734]
ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
K-ras (mutation) [HSA:3845] [KO:K07827]
AKT2 (amplification) [HSA:208] [KO:K04456]
PIK3CA (amplification) [HSA:5290] [KO:K00922]
c-MYC (overexpression) [HSA:4609] [KO:K04377]
p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
治療薬   
シクロホスファミド水和物 [DR:D00287]
イホスファミド [DR:D00343]
フルオロウラシル [DR:D00584]
ゲムシタビン塩酸塩 [DR:D01155]
ブレオマイシン塩酸塩 [DR:D03229]
ドキソルビシン塩酸塩 [DR:D01275]
エピルビシン塩酸塩 [DR:D02214]
アクラルビシン塩酸塩 [DR:D01911]
ピラルビシン塩酸塩 [DR:D08386]
ビンブラスチン硫酸塩 [DR:D01068]
エトポシド [DR:D00125]
パクリタキセル [DR:D00491]
ドセタキセル水和物 [DR:D02165]
ドセタキセル [DR:D07866]
ノギテカン塩酸塩 [DR:D02168]
イリノテカン塩酸塩水和物 [DR:D01061]
シスプラチン [DR:D00275]
カルボプラチン [DR:D01363]
ベバシズマブ [DR:D06409]
オラパリブ [DR:D09730] (BRCA遺伝子変異陽性)
ニラパリブトシル酸塩水和物 [DR:D11895]
ネダプラチン [DR:D01416]
コメント  
ICD-O: 8441/3, Tumor type: Adenocarcinoma
ICD-O: 8480/3, Tumor type: Adenocarcinoma
ICD-O: 8380/3, Tumor type: Adenocarcinoma, not otherwise specified
ICD-O: 8310/3, Tumor type: Adenocarcinoma
ICD-O: 9000/3, Tumor type: Malignant Brenner tumor
リンク   
ICD-11: 2C73
ICD-10: C56
MeSH: D010051
文献    
PMID:15111296 (tumor type)
  著者
Shih IeM, Kurman RJ.
  タイトル
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
  雑誌
Am J Pathol 164:1511-8 (2004)
DOI:10.1016/S0002-9440(10)63708-X
文献    
PMID:12886939 (gene, tumor type)
  著者
Katabuchi H, Okamura H.
  タイトル
Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.
  雑誌
Med Electron Microsc 36:74-86 (2003)
DOI:10.1007/s00795-002-0196-6
文献    
  著者
Wenham RM, Lancaster JM, Berchuck A.
  タイトル
Molecular aspects of ovarian cancer.
  雑誌
Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)
DOI:10.1053/beog.2002.0298

» English version

DBGET integrated database retrieval system